No Data
No Data
Cisen Pharmaceutical Names Chief Financial Officer
Cisen Pharmaceutical (SHA:603367) appointed one of its directors, Xu Xinbing, as chief financial officer, according to the company's filing on the Shanghai Stock Exchange. Xu will take over from Du Zh
Chenxin Pharmaceutical (603367.SH) announced its 2023 annual results, with net profit of 521 million yuan, an increase of 48.97% over the previous year
Chenxin Pharmaceutical (603367.SH) disclosed its 2023 annual report, and the company achieved 44 revenue in 2023...
Cisen Pharmaceutical's (SHSE:603367) Earnings Trajectory Could Turn Positive as the Stock Rises 6.9% This Past Week
For many, the main point of investing is to generate higher returns than the overall market. But in any portfolio, there will be mixed results between individual stocks. So we wouldn't blame long te
Chen Xin Pharmaceutical (603367.SH): Fodu Pharmaceutical plans to apply for listing on the Beijing Stock Exchange
Gelonghui, January 3, 丨 Chenxin Pharmaceutical (603367.SH) announced that the company held the 26th meeting of the 4th board of directors and the 25th meeting of the 4th board of supervisors on January 3, 2024. The meetings separately reviewed and passed the “Proposal on the Holding Subsidiary Shandong Chenxin Fodu Pharmaceutical Co., Ltd. to apply for listing on the Beijing Stock Exchange”. The board of directors agreed to the holding subsidiary Fodu Pharmaceutical planning to apply for listing on the Beijing Stock Exchange.
Cisen Pharmaceutical (SHSE:603367) Has A Rock Solid Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much
Chenxin Pharmaceutical (603367.SH): Terminate plans to spin-off the holding subsidiary Fodu Pharmaceutical to list on the main board of the Shenzhen Stock Exchange and apply for listing on the new third board
On December 1, Gelonghui (603367.SH) announced that Chenxin Pharmaceutical () announced that the board of directors agreed to stop planning for the spin-off of the holding subsidiary Shandong Chenxin Fodu Pharmaceutical Co., Ltd. (“Fodu Pharmaceutical”) to the main board of the Shenzhen Stock Exchange, and agreed that Fodu Pharmaceutical should apply for listing on the National SME Share Transfer System (New Third Board). After listing, Fodu Pharmaceutical will seek an opportunity to go public on the Beijing Stock Exchange according to the future capital market environment and strategic development needs.
No Data